PDE4A and early-onset autosomal dominant Alzheimer disease: The present findings substantiate the rich therapeutic promise of subtype selective PDE4 inhibitors for treating a range of CNS disorders including neuropsychiatric diseases such as major depressive disorder and neurological disorders such as Alzheimer’s disease.